Grufity logoGrufity logo
StocksFundsSearch Filings

Mirati Therapeutics Inc Stock Research

MRTX

38.40USD-5.44(-12.41%)Market Closed

Market Summary

USD38.40-5.44
Market Closed
-12.41%

MRTX Stock Price

MRTX RSI Chart

MRTX Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

118.18

EV/EBITDA

-2.7

Price/Free Cashflow

-3.7

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-5953.35%

Return on Equity

-74.35%

Return on Assets

-61.6%

Free Cashflow Yield

-27.06%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

18.9M

Revenue Y/Y

-73.94%

Revenue Q/Q

667.34%

MRTX Earnings

Earnings (TTM)

-737.1M

Earnings Y/Y

2.02%

Earnings Q/Q

8.84%

Price Action

52 Week Range

32.96101.30
(Low)(High)

Last 7 days

-5.7%

Last 30 days

1.2%

Last 90 days

-4.6%

Trailing 12 Months

-25.4%

MRTX Financial Health

Current Ratio

6.96

MRTX Investor Care

Shares Dilution (1Y)

4.75%

Diluted EPS (TTM)

-12.97

Peers (Alternatives to Mirati Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
310.3B
1.6B
-8.12% 92.29%
-161.87
199.29
77.54% 1.62%
285.4B
56.7B
-13.97% -3.48%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-7.48% 7.49%
20.2
7.2
-25.07% -47.28%
85.7B
9.2B
0.30% 24.35%
26.28
9.3
15.86% 32.99%
23.1B
1.0B
-9.21% 46.34%
-21.7
22.28
22.88% -19.27%
12.0B
975.7M
3.69% 90.82%
-10.76
12.3
27.41% -212.78%
9.9B
2.0B
-6.22% -2.22%
13.62
5
12.05% 52.86%
MID-CAP
5.1B
504.0K
-4.45% 362.54%
-16.36
2.5K
-66.53% -27.52%
3.5B
363.3M
14.61% 9.13%
-4.95
9.64
3.39% -55.81%
3.3B
204.6M
20.71% 4.83%
-5.64
16.03
-7.52% 10.65%
2.2B
18.9M
1.15% -25.44%
-3.03
118.18
- -16.17%
SMALL-CAP
3.6B
-
-0.47% -0.26%
-8.26
37.64
34.30% -67.22%
1.2B
256.5M
-28.87% 71.03%
12.35
4.79
66.85% 120.61%
318.5M
165.3M
-20.15% 43.43%
-3.49
1.93
130.70% 57.97%
43.9M
881.7K
8.16% 3439.25%
-0.87
19.11
-77.61% -29.84%

Financials for Mirati Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue51.9%18,894,00012,436,000
Operating Expenses2.1%788,088,000772,025,000756,742,000716,160,000697,779,000
  S&GA Expenses8.1%259,337,000239,798,000212,512,000186,897,000162,280,000
  R&D Expenses-0.8%527,334,000531,627,000544,230,000529,263,000535,499,000
EBITDA0.8%-737,430,000-743,254,000-576,350,000--
EBITDA Margin--59.30----
Earnings Before Taxes0.7%-740,359,000-745,854,000---
EBT Margin--59.53----
Net Income0.5%-737,067,000-740,867,000-738,012,000-644,505,000-634,490,000
Net Income Margin--59.57----
Free Cahsflow1.9%-575,421,000-586,445,000-496,437,000-448,681,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-14.0%1,0341,2031,3031,2801,421
  Current Assets-15.3%9391,1091,2261,2031,343
    Cash Equivalents3.1%243235299266305
  Inventory27.5%4.003.00---
  Net PPE-2.0%17.0018.0018.0017.0017.00
Liabilities-17.0%171206174168172
  Current Liabilities-21.9%125159127119124
Shareholder's Equity-13.4%8639971,1291,1121,249
  Retained Earnings-7.5%-2,637-2,452-2,250-2,076-1,900
  Additional Paid-In Capital1.4%3,5023,4533,3863,1853,145
Shares Outstanding0.5%58.0058.0058.0056.0056.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-5.2%-600,283-570,570-579,755-488,978-438,853
  Share Based Compensation2.2%190,244186,188158,459142,400131,685
Cashflow From Investing64.5%371,399225,803-4,332-17,573-83,818
Cashflow From Financing-0.5%166,144166,944640,306491,433497,864

Risks for MRTX

What is the probability of a big loss on MRTX?

99.2%


Probability that Mirati Therapeutics stock will be more than 20% underwater in next one year

88.1%


Probability that Mirati Therapeutics stock will be more than 30% underwater in next one year.

68.5%


Probability that Mirati Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Mirati Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for MRTX

Cumulative Returns on MRTX

75.6%


10-Year Cumulative Returns

13.7%


7-Year Cumulative Returns

-0.2%


5-Year Cumulative Returns

-24.4%


3-Year Cumulative Returns

What are the long-term rolling returns for MRTX?

FIve years rolling returns for Mirati Therapeutics.

Annualized Returns

Which funds bought or sold MRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
AMERIPRISE FINANCIAL INC
sold off
-100
-28,869,000
-
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
0.36
-1,850,000
8,634,000
0.01%
2023-05-18
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
unchanged
-
-1,983,720
9,071,920
2.53%
2023-05-18
JPMORGAN CHASE & CO
added
39.16
276,000
2,225,000
-%
2023-05-17
Thrivent Financial for Lutherans
reduced
-46.3
-3,379,000
2,662,000
0.01%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-474,912
-
-%
2023-05-16
JANE STREET GROUP, LLC
reduced
-21.6
-3,074,290
5,544,580
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
435
10,414,800
13,481,900
-%
2023-05-16
Utah Retirement Systems
sold off
-100
-348,887
-
-%
2023-05-16
Castleview Partners, LLC
sold off
-100
-226
-
-%

1–10 of 40

Latest Funds Activity

Are funds buying MRTX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MRTX
No. of Funds

Mirati Therapeutics News

Nasdaq
Noteworthy Thursday Option Activity: AI, AMBA, MRTX.
Nasdaq,
5 hours ago
Best Stocks
Investing.com South Africa
Mirati Therapeutics Phase 3 SAPPHIRE Study Evaluating ....
Investing.com South Africa,
29 hours ago

Schedule 13G FIlings of Mirati Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
armistice capital, llc
6.06%
3,488,000
SC 13G
Feb 14, 2023
avoro capital advisors llc
9.6%
5,555,555
SC 13G/A
Feb 14, 2023
rtw investments, lp
6.3%
3,643,114
SC 13G
Feb 14, 2023
perceptive advisors llc
3.8%
2,191,425
SC 13G/A
Feb 09, 2023
vanguard group inc
8.64%
4,973,888
SC 13G/A
Feb 06, 2023
wellington management group llp
5.24%
3,016,335
SC 13G/A
Feb 15, 2022
perceptive advisors llc
5.9%
3,283,783
SC 13G/A
Feb 11, 2022
avoro capital advisors llc
9.2%
5,075,000
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
wellington management group llp
5.70%
3,145,632
SC 13G

MRTX Fair Value

Recent SEC filings of Mirati Therapeutics

View All Filings
Date Filed Form Type Document
May 24, 2023
8-K
Current Report
May 24, 2023
4
Insider Trading
May 12, 2023
S-8
Employee Benefits Plan
May 12, 2023
8-K
Current Report
May 09, 2023
8-K
Current Report
May 09, 2023
10-Q
Quarterly Report
Apr 06, 2023
DEF 14A
DEF 14A
Apr 05, 2023
ARS
ARS
Feb 28, 2023
8-K
Current Report
Feb 28, 2023
10-K
Annual Report

Latest Insider Trading transactions for MRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-24
Christensen Jamie
sold
-28,034
45.2905
-619
evp & chief scientific officer
2023-01-20
FUCHS HENRY J
acquired
-
-
4,444
-
2023-01-20
Johnson Craig A
acquired
-
-
4,444
-
2023-01-20
Meek David D.
acquired
-
-
89,379
chief executive officer
2023-01-20
Christensen Jamie
acquired
-
-
26,864
evp, chief scientific officer
2023-01-20
Cherrington Julie M
acquired
-
-
4,444
-
2023-01-20
Stelzer Laurie
acquired
-
-
26,864
cfo
2023-01-20
Sharp Shalini
acquired
-
-
4,444
-
2023-01-20
Hickey Benjamin
acquired
-
-
36,394
evp, chief commercial officer
2023-01-20
Hasnain Faheem
acquired
-
-
6,333
-

1–10 of 50

David D. Meek
420
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Total revenue$ 7,167$ 709
Revenue  
Total revenue7,167709
Operating expenses  
Cost of product revenue5580
Cost of product revenue - intangible asset amortization2590
Research and development126,683130,976
Selling, general and administrative73,49053,951
Total operating expenses200,990184,927
Loss from operations(193,823)(184,218)
Other income (expense), net9,237(4,168)
Net loss(184,586)(188,386)
Foreign currency translation adjustment(31)0
Unrealized gain (loss) on available-for-sale investments2,043(4,802)
Comprehensive loss$ (182,574)$ (193,188)
Basic net loss per share (USD per share)$ (3.18)$ (3.40)
Diluted net loss per share (USD per share)$ (3.18)$ (3.40)
Weighted average common shares outstanding, basic (shares)58,031,64255,468,851
Weighted average common shares outstanding, diluted (shares)58,031,64255,468,851
Product Revenue  
Total revenue$ 6,291$ 0
Revenue  
Total revenue6,2910
License and Collaboration Revenue  
Total revenue876709
Revenue  
Total revenue$ 876$ 709

MRTX Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 241,925$ 235,260
Short-term investments660,369848,577
Accounts receivable, net6,227865
Inventory3,8493,020
Other current assets26,98021,239
Total current assets939,3501,108,961
Property and equipment, net17,18517,540
Intangible asset, net14,65514,914
Long-term investment3,3533,465
Right-of-use asset35,78336,122
Other long-term assets23,43521,645
Total assets1,033,7611,202,647
Current liabilities  
Accounts payable22,32038,861
Accrued liabilities102,280120,587
Total current liabilities124,600159,448
Lease liability43,22743,661
Other liabilities3,3043,022
Total liabilities171,131206,131
Commitments and contingencies (see Note 11)
Shareholders' equity  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both March 31, 2023 and December 31, 202200
Common stock, $0.001 par value; 100,000,000 authorized; 58,148,416 and 57,854,559 issued and outstanding at March 31, 2023 and December 31, 2022, respectively5858
Additional paid-in capital3,501,7543,453,066
Accumulated other comprehensive loss(1,707)(3,719)
Accumulated deficit(2,637,475)(2,452,889)
Total shareholders' equity862,630996,516
Total liabilities and shareholders' equity$ 1,033,761$ 1,202,647